Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alpha Tau Medical Ltd. - Warrant
(NQ:
DRTSW
)
0.3200
+0.1100 (+52.38%)
Streaming Delayed Price
Updated: 2:53 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6,199
Open
0.2100
Bid (Size)
0.2000 (50)
Ask (Size)
0.3368 (2)
Prev. Close
0.2100
Today's Range
0.2100 - 0.3200
52wk Range
0.0883 - 0.3325
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
December 18, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
December 17, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Performance
YTD
+40.72%
+40.72%
1 Month
+87.68%
+87.68%
3 Month
+64.10%
+64.10%
6 Month
+28.00%
+28.00%
1 Year
+39.68%
+39.68%
More News
Read More
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
October 21, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Treats First Patient with Recurrent Lung Cancer
October 10, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
September 20, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
June 25, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
May 13, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
November 28, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
November 20, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
October 30, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
October 24, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
September 14, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
August 17, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
May 17, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
May 11, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial
April 03, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial
March 08, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases
March 01, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau to Present at Upcoming November Investor Conferences
November 09, 2022
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology
October 21, 2022
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.